Table 2.

Linear studies and threshold limits of the ARs and PhACs.

N°	Compound	Group	Linear Range (ng g−1)	R2	p-Value (Mandel Test) a	LOD (ng g−1)	LOQ (ng g−1)
1	Sulfanilamide	PhACs	1.56–25	0.9989	0.1611	1.560	2.5
2	Sulfacetamide	PhACs	0.195–50	0.9995	0.5511	0.195	0.5
3	Metronidazole	PhACs	0.195–25	0.9977	0.4488	0.195	0.5
4	Sulfadiacine	PhACs	0.195–50	0.9996	0.4122	0.195	0.5
5	Sulfapyridine	PhACs	0.39–50	0.999	0.2055	0.390	0.5
6	Sulfameracine	PhACs	0.39–25	0.9986	0.9810	0.390	1.0
7	Sulfametizole	PhACs	1.56–25	0.9945	0.2324	1.560	10.0
8	Sulfametacine	PhACs	0.39–25	0.9972	0.1826	0.390	0.5
9	Sulfametoxipiridacine	PhACs	0.39–25	0.9974	0.9264	0.390	0.5
10	Sulfachloropiridacine	PhACs	0.39–25	0.9931	0.4149	0.390	2.5
11	Sulfametoxazole	PhACs	0.195–25	0.9989	0.1782	0.195	2.5
12	Sulfamonomethoxine	PhACs	0.78–50	0.9956	0.0696	0.780	1.0
13	Sulfadoxine	PhACs	0.195–25	0.9996	0.3357	0.195	0.5
14	Sulfisoxazole	PhACs	0.78–25	0.9975	0.8231	0.780	1.0
15	Chloramphenicol	PhACs	6.25–50	0.9900	0.8866	6.250	20.0
16	Sulfadimetoxine	PhACs	0.195–50	0.9998	0.1956	0.195	0.5
17	Sulfaquinoxaline	PhACs	0.78–50	0.9987	0.0582	0.780	1.0
18	Cefuroxime axetil (two isomers)	PhACs	0.39–50	0.9929	0.3722	0.390	1.0
19	Oxfendazole	PhACs	0.39–50	0.9998	0.3931	0.390	0.5
20	Penicillin V	PhACs	1.56–25	0.9987	0.8550	1.560	2.5
21	Mebendazole	PhACs	0.195–50	0.9997	0.1391	0.195	0.5
22	Cloxacillin	PhACs	1.56–50	0.9904	0.1094	1.560	2.5
23	Dexamethasone	PhACs	1.56–50	0.9974	0.0826	1.560	5.0
24	Albendazole	PhACs	0.097–25	0.9969	0.6387	0.097	0.5
25	Ketoprofen	PhACs	0.39–50	0.9985	0.7022	0.390	0.5
26	Josamycin	PhACs	0.39–25	0.9994	0.4666	0.390	1.0
27	Naproxen	PhACs	3.125–50	0.9918	0.3095	3.125	20.0
28	Cortiscosterone	PhACs	1.56–25	0.9974	0.6711	1.560	5.0
29	Fenbendazole	PhACs	0.048–25	0.9979	0.5551	0.048	0.5
30	Flunixin	PhACs	0.097–25	0.9997	0.4675	0.097	0.5
31	Imipenem	PhACs	6.25–50	0.9996	0.2499	6.250	50.0
32	Diclofenac	PhACs	0.097–50	0.9938	0.7354	0.097	2.5
33	Mefenamic acid	PhACs	0.78–25	0.9967	0.1425	0.780	10.0
34	Tolfenamic acid	PhACs	6.25–50	0.9971	0.4907	6.250	10.0
35	Eprinomectin	PhACs	0.78–25	0.9974	0.2500	0.780	2.5
36	Moxidectin	PhACs	1.56–25	0.9972	0.1269	1.560	20.0
37	Warfarin	ARs	0.39–25	0.9941	0.1400	0.390	1.0
38	Coumatetralyl	ARs	0.195–25	0.9977	0.1055	0.195	2.5
39	Bromadiolone	ARs	0.195–25	0.9991	0.1691	0.195	1.0
40	Difenacoum	ARs	0.097–50	0.9943	0.2221	0.097	1.0
41	Flocoumafen	ARs	0.024–50	0.9983	0.2167	0.024	1.0
42	Brodifacoum	ARs	0.097–50	0.9997	0.5200	0.195	1.0
43	Difethialone	ARs	3.125–50	0.9946	0.0797	3.125	20.0

^a According to Mandel’s test, the null hypothesis (H0) would indicate that the linear model is adequate to describe the calibration data. Since p-value > 0.05 in the range indicated in the table, we accept the H0 and would conclude that the linear model is adequate or reasonable to model the calibration data within this range.